SOLICITATION NOTICE
A -- A Pooled Investigation of Circulating Adiponectin Levels and risk of Multiple Myeloma - Statement of Work
- Notice Date
- 8/8/2013
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions-Treatment and Support Branch, Bldg 244, Room 112, Frederick, Maryland, 21702
- ZIP Code
- 21702
- Solicitation Number
- N01CP34404-11
- Archive Date
- 9/7/2013
- Point of Contact
- Brenda Oberholzer, Phone: 301-228-4216, Brian Madgey, Phone: 301 624-8760
- E-Mail Address
-
oberholzerb@mail.nih.gov, brian.madgey@nih.gov
(oberholzerb@mail.nih.gov, brian.madgey@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Statement of Work General Information Title: A Pooled Investigation of Circulating Adiponectin Levels and Risk of Multiple Myeloma Document Type: Presoliciation Notice Posted Date: 8/8/2013 Response Date: 8/23/2013 Classification Code: Q301 Laboratory Testing Services NAICS Code: 541711 Research and Development in Biotechnology Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, Riverside Five, Suite 400, Room 4025, Frederick, MD 21701, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), is anticipating to award a Firm-Fixed Price non-competitive purchase order to Jewish General Hospital in Montreal, Canada to provide analytes measurements that are scientifically comparable with prior findings. The services herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106-1 (b)(1). The North American Industry Classification System code is 541711 and the business size standard is 500 Employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance shall be for twelve (12) months from date of award. It has been hypothesized that the observed excess risk of multiple myeloma (MM) among obese individuals could be due to altered circulating levels of andiponectin, a polypeptide hormone with anti-inflammatory properties secreted by adipose tissue. In a recent prospective investigation of 174 MM cases and 348 controls in the Prostate, Lung, Colorectal, and Ovarian Screening Trial, we observed inverse associations with MM for both total and high-molecular-weight (HMW) adiponectin. The results of this study suggest that adiponectin may play a role in obesity-related myelomagenesis, although replication of these findings in other prospective cohorts is critical. Findings from other recent studies suggest that altered circulating levels of resistin, another hormone secreted by adipose tissue, may also influence MM risk. In an effort to replicate our PLCO findings for adiponectin and extend our investigation to resistin, we are conducting a pooled nested case-control study using prospectively collected blood samples from six cohorts participating in the NCI Cohort Consortium. The laboratory of Dr. Michael Pollak located at Jewish General Hospital has performed assays measuring circulating adipokine levels for a number of previous studies by NCI investigators, including our previous investigation of multiple myeloma in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. The laboratory has considerable experience measuring these analytes with excellent reproducibility. For scientific comparability with prior findings, it is critical that the laboratory measurements of these analytes for the proposed replication effort be carried out in the laboratory at Jewish General Hospital. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 12:00 PM EST, on August 23, 2013. For further information, please contact Brenda Oberholzer, Contracting Officer via electronic mail at oberholzerb@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) thru sam.gov. Reference: NCI-34404-11 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/FCRF2/N01CP34404-11/listing.html)
- Record
- SN03142756-W 20130810/130808235948-a0b17897c1f3da4b54ac0971135aae71 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |